Compounds > ciclopirox
Page last updated: 2024-10-25

ciclopirox and Atypical Ductal Hyperplasia

ciclopirox has been researched along with Atypical Ductal Hyperplasia in 2 studies

Research Excerpts

ExcerptRelevanceReference
"DCIS is treated by surgery and possibly radiotherapy."1.72Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy. ( Al-Zubaydi, F; Chan, N; Gao, D; Holloway, J; Kakkar, D; Kumar, S; Li, S; Love, S; Sabaawy, HE; Sinko, PJ; Szekely, Z, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Al-Zubaydi, F2
Gao, D2
Kakkar, D2
Li, S2
Adler, D1
Holloway, J2
Szekely, Z2
Gu, Z1
Chan, N2
Kumar, S2
Love, S2
Sinko, PJ2
Sabaawy, HE1

Other Studies

2 other studies available for ciclopirox and Atypical Ductal Hyperplasia

ArticleYear
Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy.
    Journal of controlled release : official journal of the Controlled Release Society, 2020, 07-10, Volume: 323

    Topics: Animals; Breast; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ciclopirox; Drug Deliver

2020
Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.
    Drug delivery and translational research, 2022, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ciclopiro

2022